Proper B cell tolerance ensures effective censoring of autoreactive B cells thereby avoiding their participation in effector pathogenic response and preventing autoimmune diseases. The breakdown of B cell tolerance is at the core Systemic Lupus Erythematosus and may in fact, represent the initiating step in the cascade of pathogenic events leading to clinical disease. While B cell tolerance is relatively well understood in transgenic mouse models, human B cell tolerance remains poorly understood due to the lack of informative systems and inherent experimental limitations. To remedy these problems, we have concentrated over the last few years in the study of autoreactive 9G4 B cells, which represent an abundant and homogeneous population of autoreactive B cells that are strictly censored in healthy subjects but not in SLE. Our results demonstrate that normal censoring of 9G4 cells is achieved through a combination of mechanisms including germinal center (GC) exclusion, anergy and positive selection into the marginal zone compartment due at least in part to receptor editing. We have also demonstrated that SLE 9G4 cells are expanded in newly identified effector B cell populations in patients with active disease, presumably reflecting the malfunction of GC and late checkpoints. This application will provide a detailed understanding of human B cell tolerance and its breakdown in SLE by pursuing the following Aims: 1) To elucidate the role of receptor editing and antigen selection in human B cell tolerance;2) To understand antigen-driven selection of effector autoimmune B cells in SLE. The expected information will substantially advance our understanding of the regulation of autoreactive B cells while also identifying B cell markers and autoimmune specificities with great potential as biomarkers, diagnostic and therapeutic targets.
Autoimmune diseases like SLE are triggered by lack of regulation of cells that recognize our own antigens. Understanding the regulation of these cells (called autoreactive B cells) will be of great importance for the diagnosis of treatment of multiple autoimmune diseases also including Rheumatoid Arthritis and Diabetes. We will use a well-recognized subset of human autoreactive B cells (termed 9G4) that are specifically defective in patients with SLE. Using molecular and cellular approaches, we will elucidate the mechanisms, antigens and precise points of deregulation of these cells.
|Wilmore, Joel R; Asito, Amolo S; Wei, Chungwen et al. (2015) AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus. Int J Cancer 136:1371-80|
|Sanz, Iñaki (2014) Rationale for B cell targeting in SLE. Semin Immunopathol 36:365-75|
|Roberts, Mustimbo E P; Kaminski, Denise; Jenks, Scott A et al. (2014) Primary Sjögren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol 66:2558-69|
|Richardson, Christopher; Chida, Asiya Seema; Adlowitz, Diana et al. (2013) Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol 191:4926-39|
|Oleksyn, David; Pulvino, Mary; Zhao, Jiyong et al. (2013) Protein kinase Cýý is required for lupus development in Sle mice. Arthritis Rheum 65:1022-31|
|Kobie, James J; Alcena, Danielle C; Zheng, Bo et al. (2012) 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. PLoS One 7:e35356|
|Ching, Kathryn H; Burbelo, Peter D; Tipton, Christopher et al. (2012) Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 7:e32001|
|Quach, Tam D; Manjarrez-Orduno, Nataly; Adlowitz, Diana G et al. (2011) Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J Immunol 186:4640-8|
|Wei, Chungwen; Jung, John; Sanz, Inaki (2011) OMIP-003: phenotypic analysis of human memory B cells. Cytometry A 79:894-6|
|Calero, Ismael; Sanz, Iñaki (2010) Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med 10:416-24|